TALPHERA, INC. Segments Disclosure
15. Segment Information
The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company has reportable segment, which is the development and commercialization of innovative therapies for use in medically supervised settings.
The Company’s chief operating decision maker, or CODM, which consists of its Chief Executive Officer and the Chief Financial Officer, reviews the Company’s operating results on an aggregate basis and manages the Company’s operations. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations. The CODM uses consolidated net loss to evaluate the Company's spend and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing performance of the segment and in establishing resource allocation across the organization.
The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.
The segment derives its revenues in the United States pursuant to the Marketing Agreement with Alora. All long-lived assets are maintained in the United States.
The table below is a summary of the segment loss, including significant segment expenses (in thousands):
|
Year ended |
||||||||
| December 31, | ||||||||
|
2025 |
2024 |
|||||||
|
Revenue |
$ | (28 | ) | $ | — | |||
|
Less: |
||||||||
|
Employee expense (not including stock-based compensation) |
5,823 | 6,212 | ||||||
|
Development and clinical trial expense |
3,227 | 3,385 | ||||||
|
Other general and administrative expense(a) |
3,666 | 4,376 | ||||||
|
Other segment loss (income), net(b) |
1,675 | (969 | ) | |||||
|
Discontinued operations |
(73 | ) | — | |||||
|
Segment and consolidated net loss |
$ | (14,290 | ) | $ | (13,004 | ) | ||
(a)Other general and administrative expense includes consulting and professional services fees, insurance, facilities and other corporate expenses.
(b)Other segment loss (income), net includes gain on sale of future payments, fair value adjustments to warrant liability, interest income and expense, and stock-based compensation expense and marketing support.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 23, 2026 | Showing above |
| 2024 | Mar 31, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.